tradingkey.logo

Anbio Biotechnology

NNNN
32.350USD
+2.100+6.94%
收盤 12/19, 16:00美東報價延遲15分鐘
4.65B總市值
1939.45本益比TTM

Anbio Biotechnology

32.350
+2.100+6.94%

關於 Anbio Biotechnology 公司

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Anbio Biotechnology簡介

公司代碼NNNN
公司名稱Anbio Biotechnology
上市日期Feb 19, 2025
CEOLau (Michael)
員工數量27
證券類型Ordinary Share
年結日Feb 19
公司地址Friedrich-Ebert-Anlage 49
城市FRANKFURT AM MAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Germany
郵編60308
電話4916096247281
網址https://anbiobiotechnology.com/
公司代碼NNNN
上市日期Feb 19, 2025
CEOLau (Michael)

Anbio Biotechnology公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--
Mr. Chris Tiantian
Mr. Chris Tiantian
Chief Business Officer
Chief Business Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Nancy Hartzler
Ms. Nancy Hartzler
Independent Director
Independent Director
--
--
Mr. David Hsu
Mr. David Hsu
Independent Director
Independent Director
--
--
Mr. Kenneth Li
Mr. Kenneth Li
Independent Director
Independent Director
--
--
Mr. Michael Lau
Mr. Michael Lau
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Suki Song
Ms. Suki Song
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cany Xu
Mr. Cany Xu
Executive Director
Executive Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
European Union
5.62M
68.64%
South America
1.48M
18.02%
Asia Pacific
509.17K
6.22%
Other Regions
472.38K
5.77%
North America
110.51K
1.35%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
其他
90.33%
持股股東
持股股東
佔比
Northwestern Mutual Capital, LLC
4.78%
CVC Investment
4.78%
Geode Capital Management, L.L.C.
0.06%
Marshall Wace LLP
0.02%
Morgan Stanley & Co. LLC
0.02%
其他
90.33%
股東類型
持股股東
佔比
Investment Advisor
4.80%
Corporation
4.78%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.03%
Hedge Fund
0.02%
Venture Capital
0.02%
其他
90.28%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
8
2.13M
4.85%
+2.06M
2025Q2
5
4.27M
9.72%
+4.25M
2025Q1
5
4.27M
9.72%
+4.27M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Northwestern Mutual Capital, LLC
2.10M
4.78%
+2.10M
--
Feb 19, 2025
CVC Investment
2.10M
4.78%
+2.10M
--
Feb 19, 2025
Geode Capital Management, L.L.C.
17.13K
0.04%
+70.00
+0.41%
Jun 30, 2025
Marshall Wace LLP
--
0%
-43.63K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
400.00
0%
+400.00
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
1.26K
0%
+1.26K
--
Jun 30, 2025
UBS Financial Services, Inc.
10.70K
0.02%
+4.96K
+86.39%
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Anbio Biotechnology的前五大股東是誰?

Anbio Biotechnology的前五大股東如下:
Northwestern Mutual Capital, LLC
持有股份:2.10M
佔總股份比例:4.78%。
CVC Investment
持有股份:2.10M
佔總股份比例:4.78%。
Geode Capital Management, L.L.C.
持有股份:17.13K
佔總股份比例:0.04%。
Marshall Wace LLP
持有股份:0.00
佔總股份比例:0.00%。
Morgan Stanley & Co. LLC
持有股份:400.00
佔總股份比例:0.00%。

Anbio Biotechnology的前三大股東類型是什麼?

Anbio Biotechnology 的前三大股東類型分別是:
Northwestern Mutual Capital, LLC
CVC Investment
Geode Capital Management, L.L.C.

有多少機構持有Anbio Biotechnology(NNNN)的股份?

截至2025Q3,共有8家機構持有Anbio Biotechnology的股份,合計持有的股份價值約為2.13M,占公司總股份的4.85% 。與2025Q2相比,機構持股有所增加,增幅為-4.87%。

哪個業務部門對Anbio Biotechnology的收入貢獻最大?

在FY2024,--業務部門對Anbio Biotechnology的收入貢獻最大,創收--,占總收入的--% 。
KeyAI